# A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

> **NCT00000754** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 60 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Interferon alfa-2a
- **DRUG:** Zidovudine
- **DRUG:** Zalcitabine

## Key facts

- **NCT ID:** NCT00000754
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1995-02
- **Target enrollment:** 60 (—)
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000754, "A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*